Selank Peptide: Recent 2026 Research

Selank (TP-7), a synthetic heptapeptide developed in Russia, continues to attract research interest for its potential effects on anxiety, mood, and cognition. This article summarizes the latest 2026 preclinical findings on Selank's mechanisms—focusing on anxiolytic pathways, BDNF signaling, and immune modulation—and clarifies the current state of human evidence.

What is Selank?

Selank (sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro; molecular weight 751.87 Da) was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is not FDA-approved in the United States but has been used as an anxiolytic medication in Russia and some Eastern European countries. In the research community, it is studied strictly as an experimental compound in preclinical and limited clinical settings.

2026 research findings: mechanisms of action

Recent studies continue to focus on three main areas of Selank activity:

• GABA and anxiolytic pathways. Preclinical evidence suggests Selank may modulate GABAergic neurotransmission, the primary mechanism of benzodiazepines. Animal models show anxiolytic-like behavior in elevated-plus-maze and other anxiety tests.
• BDNF and neuroplasticity. Studies report increased brain-derived neurotrophic factor (BDNF) expression in hippocampal and cortical regions, potentially supporting synaptic plasticity, memory consolidation, and stress resilience.
• Immune regulation. Recent work emphasizes Selank's effects on cytokine balance, particularly IL-6, TNF-α, and Th1/Th2 axis modulation, suggesting a role in stress-immune crosstalk.

Human evidence: limited but growing

The strongest human data comes from a 14-day open-label trial in anxiety patients (published ~2015), which documented changes in IL-6, TNF-α, and Th1/Th2 ratios alongside self-reported anxiety reduction. However, this study was small, had no placebo control, and has not been replicated in a rigorous, blinded format. No large randomized controlled trials in humans have been published as of 2026.

Strengths and gaps in the evidence

What the evidence supports: Selank shows consistent anxiolytic-like effects in rodent behavioral models and modulates immunological markers in both animals and small human cohorts. The peptide has minimal reported adverse effects in the studies published to date.

Major gaps: No completed Phase 2 or Phase 3 human trials. No data on optimal dosing, duration of effect, or long-term safety in humans. Most human work is from Russian or regional literature, with limited peer-reviewed English-language publications in major journals.

Clinical relevance and future directions

If Selank eventually enters serious clinical development in the West, research priorities would likely be:

• Dose-response and pharmacokinetic studies in healthy volunteers.
• Randomized, placebo-controlled trials in generalized anxiety disorder and related conditions.
• Mechanistic studies linking BDNF, cytokine changes, and behavioral outcomes.
• Comparison to established anxiolytics to define relative efficacy and safety profile.

Selank research compound

We supply Selank to the research community—HPLC-tested, with certificates of analysis on every batch, for preclinical research use:

View Selank (research grade)

Sources & further reading

• Frontiers in Aging — Therapeutic Peptides in Gerontology (2026)
• PepMate — Selank Anxiolytic Research & Safety

Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.